Products Dasatinib
Dasatinib Phase 2 Completed 💤 Quiet Interest: 35/100
Multiple Indications Cancer
Multiple Indications Cancer
Jul 31, 2015 → May 15, 2022
About Dasatinib Dasatinib is a phase 2 stage product being developed by Bristol Myers Squibb for Multiple Indications Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02297139. Target conditions include Multiple Indications Cancer.
What happened to similar drugs? 20 of 20 similar drugs in Multiple Indications Cancer were approved
Clinical Trials (20) NCT ID Phase Status Start Completion Indication NCT00454753 Pre-clinical Completed — — — NCT04115059 Phase 1 Terminated Nov 4, 2019 Dec 31, 2021 Waldenstrom Macroglobulinemia NCT02297139 Phase 2 Completed Jul 31, 2015 May 15, 2022 Multiple Indications Cancer NCT02546791 Pre-clinical Completed Jul 22, 2015 Mar 29, 2017 Leukemia NCT02428855 Phase 2 Completed Apr 1, 2015 Feb 1, 2018 Cholangiocarcinoma NCT01850004 Phase 2 Completed Jan 22, 2014 Oct 8, 2021 Chronic Phase Chronic Myeloid Leukemia NCT01471106 Phase 2 Completed Jan 21, 2014 May 30, 2024 Breast Cancer NCT02389972 Pre-clinical Completed Apr 11, 2013 Jul 13, 2017 Leukemia, Myelogenous, Chronic, BCR-ABL Positive NCT01802450 Phase 2 UNKNOWN Mar 1, 2013 Dec 1, 2016 Chronic Myeloid Leukemia NCT01660906 Approved Completed Dec 1, 2012 Oct 1, 2015 Chronic Phase Chronic Myeloid Leukemia NCT01514864 Phase 2 Terminated May 31, 2012 Jul 23, 2014 Carcinoma, Non-small Cell Lung NCT01460160 Phase 2 Completed Apr 13, 2012 Jun 1, 2021 Leukemia, Pediatric NCT01092728 Phase 2 Terminated Mar 1, 2011 Aug 1, 2014 Melanoma NCT00918463 Phase 2 Terminated Jun 1, 2009 May 23, 2011 Diffuse Large B-cell Lymphoma NCT00777036 Phase 2 Completed Mar 20, 2009 Jan 27, 2025 Leukemia NCT00858403 Phase 2 Terminated Mar 1, 2009 Jul 1, 2010 Lung Cancer NCT00764309 Phase 1/2 Completed Jan 1, 2009 Apr 1, 2011 Scleroderma NCT00787267 Phase 2 Terminated Sep 1, 2008 Jun 1, 2013 Non Small Cell Lung Cancer NCT00706641 Pre-clinical Completed Jun 1, 2008 Dec 1, 2012 Transitional Cell Carcinoma of the Bladder NCT00652574 Phase 1 Completed Mar 12, 2008 Oct 7, 2022 Malignant Pleural Mesothelioma
Product Company Stage Hype Score Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 NEX-20A Nanexa AB Phase 1 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Mirabegron + Placebo Astellas Pharma Approved Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 BIW-8962 Kyowa Kirin Phase 1 KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Kyowa Kirin Phase 2 KW-2478 + Bortezomib Kyowa Kirin Phase 1/2 ONO-2808 + Placebo Ono Pharmaceutical Phase 2 KW-2478 Kyowa Kirin Phase 1